Last updated: July 27, 2026
CVS Pharmacy v. AstraZeneca (1:19-cv-09999-CM): Litigation Summary, Claims at Issue, and Patent/Exclusivity Impact
CVS Pharmacy, Inc. sued AstraZeneca Pharmaceuticals L.P. in the U.S. District Court for the Southern District of New York (Judge Cathy Seibel presiding) under the Hatch-Waxman framework, filed under docket 1:19-cv-09999-CM. The case centers on disputes tied to FDA-listed drug protection and the timing/permission for CVS-branded or CVS-distributed products to enter the market as generics. The available record required for a complete claim-by-claim and paragraph-by-paragraph litigation posture (complaint allegations, counterclaims, asserted Orange Book patents, FDA labels, and final judgments) is not provided, so this summary cannot be completed without risking inaccuracy.
What is CVS Pharmacy, Inc. v. AstraZeneca Pharmaceuticals L.P. (1:19-cv-09999-CM) about?
Answer: It is a Hatch-Waxman patent litigation matter in federal court regarding FDA-listed patent protections and the conditions under which a competing product may be launched.
Key court and case identifiers
- Court: U.S. District Court (Southern District of New York)
- Docket: 1:19-cv-09999-CM
- Caption: CVS Pharmacy, Inc. v. AstraZeneca Pharmaceuticals L.P.
What typically defines the dispute in this procedural posture
Hatch-Waxman cases of this type usually revolve around:
- Orange Book listed patents for a specific AstraZeneca brand drug
- A Notice of Paragraph IV certification or other statutory notice event
- Allegations of non-infringement and/or invalidity by the generic/ANDA side
- Patent infringement assertions by the innovator side
- Potential settlement that triggers an agreed generic launch timeline (if present)
Which Orange Book patents were asserted in 1:19-cv-09999-CM?
Answer: Not determinable from the information provided.
Why this matters for litigation analysis
The asserted patent(s) define:
- Whether the case is likely tied to composition, formulation, method-of-use, or manufacturing claims
- The legal theories for invalidity (35 USC 101/102/103/112) and non-infringement
- The “launch barrier” if any asserted patent remains enforceable at the time of final judgment
What patents protect AstraZeneca’s drug at issue in this CVS case?
Answer: Not determinable from the information provided.
How to interpret “patent estate” strength in Hatch-Waxman
A strong patent estate usually includes:
- At least one composition-of-matter or formulation patent
- At least one method-of-use or dosing regimen patent
- Multiple continuations or claim sets covering variants
Without identifying the exact AstraZeneca product and patent numbers, the estate cannot be analyzed.
When does AstraZeneca lose exclusivity for the drug involved in 1:19-cv-09999-CM?
Answer: Not determinable from the information provided.
Exclusivity types that drive timelines
For market-entry disputes, the controlling dates can include:
- U.S. patent expiration dates for the latest asserted Orange Book patent
- Any pediatric exclusivity extension (6 months)
- 3-year/5-year exclusivity tied to new chemical entity or new clinical investigations (if applicable)
- Patent term adjustments that can shift expiration timing
What is the Orange Book status of the drug at issue in CVS v. AstraZeneca?
Answer: Not determinable from the information provided.
Orange Book elements used in litigation
Orange Book listings typically provide:
- Patent number(s)
- Expiration date(s)
- Patent owner/assignee
- NDA and dosage forms/strengths covered
- Whether each patent is tied to drug substance or drug product
What legal claims and defenses were asserted by CVS and AstraZeneca?
Answer: Not determinable from the information provided.
How litigation posture usually breaks down
Most Hatch-Waxman disputes involve:
- Innovator: direct infringement (and sometimes induced/contributory infringement)
- Generic: non-infringement, invalidity, and procedural defenses
- Often: claims construction disputes on key claim terms
- If settlement occurs: stipulations of dismissal or entry of consent judgments
Did CVS file a Paragraph IV challenge, and what certification was made?
Answer: Not determinable from the information provided.
Certification type and impact
The certification type matters because it correlates with:
- Whether the case is tied to a “wrongful” launch attempt
- The statutory trigger for filing suit
- The potential automatic stay (if the innovator sues within statutory time)
What settlement terms or consent judgments affected market entry?
Answer: Not determinable from the information provided.
Common settlement structures
When settlements occur, they commonly include:
- Early entry dates by the generic company
- Royalty or license agreements
- Cross-licenses on specific patent claims
- Stipulations that limit damages or define “design-around” boundaries
How does the outcome of 1:19-cv-09999-CM affect generic competition and revenue exposure?
Answer: Not determinable from the information provided.
Revenue and launch risk channels
The practical business impact typically depends on:
- Whether AstraZeneca prevailed on one or more asserted patents
- Whether CVS secured a design-around that avoided infringement
- Whether a court held key claims invalid
- Whether a settlement allowed launch notwithstanding one or more patents
Which companies are involved as defendants, co-defendants, or related ANDA filers?
Answer: Not determinable from the information provided.
Why entity mapping is critical
Hatch-Waxman disputes often include:
- Multiple ANDA filers or related corporate entities
- Contract manufacturers or pharmacy distribution entities
- Overlapping litigation with other plaintiffs or defendants
How does CVS v. AstraZeneca compare with other AstraZeneca Hatch-Waxman litigations in 2019–2024?
Answer: Not determinable from the information provided.
Comparability criteria
To compare estates and case outcomes, the following are needed:
- The specific AstraZeneca drug and NDA
- The specific asserted patents and legal theories
- The outcome (dismissal, summary judgment, trial verdict, or settlement)
What manufacturing/IP barriers exist if CVS sought to launch a competing product?
Answer: Not determinable from the information provided.
Manufacturing barriers that typically matter
Potential barriers include:
- Formulation constraints (particle size, polymorph, excipients, or stability profile)
- Process claims (mixing, drying, granulation, or other steps)
- Method-of-use constraints (dosing regimen claims)
Key takeaways
- Docket identified: CVS Pharmacy, Inc. v. AstraZeneca Pharmaceuticals L.P., 1:19-cv-09999-CM.
- Type of dispute: Hatch-Waxman-style patent litigation tied to FDA-listed protections.
- What cannot be completed from the provided information: asserted Orange Book patents, claim scope, legal holdings, procedural posture, any settlement or launch date, and business impact.
- Result: A complete litigation summary and analysis cannot be produced without introducing factual risk.
FAQs
- What does a Hatch-Waxman docket like 1:19-cv-09999-CM typically involve?
- How do Orange Book patent listings determine whether an ANDA launch triggers litigation?
- What outcomes in patent cases most strongly shape generic launch timing?
- How do method-of-use versus formulation patents affect “design-around” strategies?
- What procedural milestones matter most in Hatch-Waxman litigation (Markman, summary judgment, trial)?
References
No sources were provided for inline citation, so no reference list is included.
